Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.51, read 2026-10-27
Ethical does not pass the values gate
Price199.40 USD
Fair value198.08
Ethical score10.0/100
RatingAVOID
Our investment reviews on this name
2026-10-20Read Markup186.95+6.7% to today ✓Markdown gives way to Markup first Markup read since August
2026-10-02Read Markdown189.40+5.3% to today Markup gives way to Markdown after an 11% slide in 6 weeks
2026-08-22Read Markup212.29-6.1% to today Accumulation gives way to Markup after a 17% rise in 7 weeks
2026-07-02Read Accumulation180.99+10.2% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
RTX Corporation holds its Markup at $199.40. The statistical read favours the sellers, held for 61 days.
As held on the ledger · 2026-10-29
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 61 days
Price at the screen
$199.40
Valuation
32.42 trailing · 24.74 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.31
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Business activity: Aerospace & Defense
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
RTX does not clear the screen at the business-activity stage. It operates in aerospace and defense, so the financial ratios are not the deciding factor here.
Read as at 2026-10-30. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when RTX's ethical verdict changes
Today RTX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads AVOID: it trades above our $198.08 fair value estimate, narrow competitive moat, 11.10% revenue growth.
Fair value range in USD, drawn from the 2026-10-29 screen. The gold marker is the market price at the same screen. The price runs 0.7% above the base estimate.
Third-party analyst targets: 23 covering, consensus Buy. The average target sits +18% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-29 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
RTX Corporation - A High-Flying Stock, Grounded by Ethics
Consider RTX Corporation as the power behind the wings of modern aviation. The company, with its diverse segments in aerospace and defense, is at the forefront of technology, providing systems and services to a global clientele. Why it stands out, however, is not just its technological prowess but also its ethical failings. Despite a robust revenue growth of 14%, a decent profit margin of 8%, and an ROE of 12%, RTX Corporation fails our ethical screen due to certain business activities, thus classified as an AVOID.
The market consensus is bullish, with a median target price of $240, which translates to a forward P/E of 27.0x. While this indicates a potential for growth, it also suggests that the stock is not undervalued, given our fair value of $198.56. The risk here is multifaceted; the company's narrow moat indicates a lack of competitive advantage, which, combined with the ethical failings, paints a less-than-ideal picture for investors prioritizing both returns and ethical considerations.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
RTX trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-27Markup$186.95+0.0%Entry 19
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (22 analysts) rates it buy, with a mean price target of $215.
2026-10-20Markup · changed$186.95+0.0%Entry 18
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (22 analysts) rates it buy, with a mean price target of $215. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Markdown$186.95+0.0%Entry 17
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (22 analysts) rates it buy, with a mean price target of $215. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markdown$186.95+0.0%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (22 analysts) rates it buy, with a mean price target of $215. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Markdown$186.95+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (22 analysts) rates it buy, with a mean price target of $215. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Markdown$186.95+0.5%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (22 analysts) rates it buy, with a mean price target of $215. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markdown$185.97+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (22 analysts) rates it buy, with a mean price target of $215. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Markdown$185.97+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (22 analysts) rates it buy, with a mean price target of $215. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-13Markdown$185.97-1.8%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (22 analysts) rates it buy, with a mean price target of $215. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-02Markdown · changed$189.40-10.8%Entry 10
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (22 analysts) rates it buy, with a mean price target of $215.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
